



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

27 August 2020

New revenue stream added to IDTF platform

- Patients undergoing Transcatheter Aortic Valve Replacement (TAVR) treatment now being monitored through IDTF platforms – first patients enrolled
- GMV receives reimbursements per patient monitored based on the duration of monitoring
- Builds on three-fold forecast increase in patients that will be monitored in CY2020 through IDTF
- On track for solid growth in patient monitoring numbers in August

Medical device, telehealth and medical Services company **G Medical Innovations (ASX: GMV)** ("**G Medical**" or the "**Company**") is pleased to advise that it has added a new revenue stream to its Independent Diagnostic Testing Facilities (IDTF) platform.

The Company will now offer remote patient monitoring services to patients undergoing Transcatheter Aortic Valve Replacement (TAVR) treatment. Under the program, hospital partners can now monitor pre-TAVR patients through the use of G Medical's AECG Patch technology and post-TAVR patients using the Company's Mobile Cardiac Telemetry (MCT) device.

G Medical will receive reimbursements for the service through insurers. These reimbursements will vary depending on the duration of the monitoring period. In 2017, TAVR procedures accounted for over one third of the total cardiac surgery market, which was valued at US\$5.1Bn¹. The TAVR market segment has continued to grow since 2017 and is expected to scale up further in the future. First patients have been recruited through existing hospital partnerships, with revenue expected to materialise within the next 90 days.

The TAVR program is one of a number of collaborative initiatives that G Medical is undertaking to grow IDTF offering in the United States, predominantly through the US hospital sector. IDTF delivers stable and recurring revenue streams through ongoing monthly patient monitoring. Its recent success in penetrating the US hospital sector, and adding new monitoring services, will ensure these revenue streams strengthen considerably. The 2020 calendar year forecast has been well documented and will be achieved.

CEO Dr Yacov Geva, said: *"Providing hospital partners with the ability to monitor patients undergoing TAVR treatment through our IDTF platform is another valuable revenue channel. It is yet again further evidence of the growing demand we are witnessing for our services in the USA and highlights the scalability and versatility of our IDTF operations."*

"As the addressable market for telehealth grows, we are very confident IDTF will continue to scale up. We are making excellent headway in the US university hospital market and our large sales team is identifying many more opportunities for growth. More updates will be provided and we look forward to showing the progress we made in August with respect to patient monitoring numbers."

Three phase approach to IDTF platform deployment with United States university hospitals:

Evaluation:	Implementation:	Treatment:
<ul style="list-style-type: none"> Identify university hospitals and medical institutions that institutions that would benefit from cardiac monitoring technologies and services, provided through G Medical's IDTF operations. Commence discussions with a number of management personnel at a number of hospitals is ongoing. Demonstrations of G Medical's IDTF platform and medical devices with management, institutional physicians and staff. Decision is made by hospital management to implement G Medical's IDTF platform. 	<ul style="list-style-type: none"> Ongoing education, training, and support services for institutional physicians and staff. Cyber security protocols and implementation in conjunction with in-hospital IT departments. Implementation of G Medical's 'applications' into organisation mainframes. G Medical's 'Home Connect' set-up and deployment. Data management, diagnostic and related protocols. Patient selection, enrolment, medical device deployment and management protocols set. 	<ul style="list-style-type: none"> Patient enrolments commence from hospital and individualised monitoring service (24 hours to 30 days or longer) commences. G Medical to receive between US\$175 and US\$750 per patient monitored, plus a daily service fee – revenue to be booked within 90 days of enrolment. Services can include Mobile Cardiac Telemetry (MCT), Holter Monitoring and Ambulatory electrocardiography (AECG). Deployment allows for improved revenue for partner hospital and better patient care. R&D and business development work continues to broaden service offering, enhance protocols, improve efficiency and expand hospital staff knowledge base. <ul style="list-style-type: none"> Build sustainable infrastructure within Institutional partners; Medical device inventory management; Broadened direct and remote patient monitoring services; Improved cardiac rhythm disturbance protocols; Improved protocols for the placement of 'Cardiac Event Monitors' post Transcatheter aortic valve replacement (TAVR), and other procedures.

Ends

Authorised for release by Yacov Geva, Managing Director.

For more information, please contact:

Brendan De Kauwe
Director
Brendan@gmedinnovations.com

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 (0) 431 271 538

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.

ⁱ <https://idataresearch.com/product/cardiac-surgery-market-united-states/>